GLMD vs. BFRI, DWTX, PRTG, SNGX, NLSP, RNAZ, CSCI, SNOA, TLPH, and ADIL
Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Biofrontera (BFRI), Dogwood Therapeutics (DWTX), Portage Biotech (PRTG), Soligenix (SNGX), NLS Pharmaceutics (NLSP), TransCode Therapeutics (RNAZ), COSCIENS Biopharma (CSCI), Sonoma Pharmaceuticals (SNOA), Talphera (TLPH), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry.
Galmed Pharmaceuticals vs. Its Competitors
Biofrontera (NASDAQ:BFRI) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.
10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 4.8% of Biofrontera shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Biofrontera has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Galmed Pharmaceuticals and 3 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.29 beat Galmed Pharmaceuticals' score of 0.98 indicating that Biofrontera is being referred to more favorably in the media.
Galmed Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -42.34%. Galmed Pharmaceuticals' return on equity of -21.68% beat Biofrontera's return on equity.
Galmed Pharmaceuticals has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Biofrontera currently has a consensus target price of $2.75, indicating a potential upside of 210.35%. Given Biofrontera's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biofrontera is more favorable than Galmed Pharmaceuticals.
Summary
Galmed Pharmaceuticals beats Biofrontera on 9 of the 15 factors compared between the two stocks.
Get Galmed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galmed Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:GLMD) was last updated on 8/29/2025 by MarketBeat.com Staff
MarketBeat All Access